Printer Friendly

False elevations in blood glucose readings with use of icodextrin (extraneal) peritoneal dialysis solution.

Case presentation

Mr. BP is a 67-year-old male who started peritoneal dialysis (PD) three weeks ago and is coming into the PD clinic to see the multi-disciplinary team.

[ILLUSTRATION OMITTED]

His past medical history includes: Type 2 diabetes mellitus for the past eight years, a myocardial infarction three years ago and benign prostatic hypertrophy.

His current insulin regimen is:

* Insulin glargine (Lantus) 20 units at bedtime

* Insulin lispro (Humalog) 6 units with meals

His CCPD prescription is:

* Total volume: 11,000 mL * Total time: 9 hrs

* Fill volume: 1,900 mL

* Last fill: 1000 mL icodextrin

Mr. BP presents at the clinic complaining that his blood sugar levels have been higher than normal since he started peritoneal dialysis. His current A1C is 6.8%. His blood glucose meter readings have been between 10 mmol/L and 15 mmol/L and he has been increasing his dose of fast-acting insulin to accommodate for this, which has resulted in one or two hypoglycemic episodes. He is wondering if he should increase his long-acting insulin instead and questions if the dialysis sugar solutions are the cause of his poor diabetes control.

Icodextrin

Icodextrin is a starch-derived polymer indicated for a single daily peritoneal dialysis exchange. It is typically used in the long (8to 16-hour) dwell during continuous ambulatory peritoneal dialysis (CAPD) or automated peritoneal dialysis (APD) (Baxter, n.d.). Since this solution is commonly used, nephrology health care practitioners and patients must be aware of its potential drug-lab interaction with blood glucose meters. Icodextrin PD solutions can falsely elevate blood glucose levels and lead to erroneous administration of insulin, which may result in hypoglycaemia complications (Health Canada, 2008). As a result, warnings have been issued by Health Canada and the manufacturer of blood glucose meters and icodextrin PD solutions.

The drug-lab interaction with blood glucose meters occurs as a result of the absorption and subsequent metabolism of icodextrin. Approximately 40% of icodextrin is absorbed during a 12-hour dwell via the lymphatic system and then moves into the blood stream (Baxter, n.d.). Within the blood circulation, amylases break down the icodextrin into oligosaccharides including maltose (Riley, Chess, Donovan, & Williams, 2003). The maltose by-product can contribute to the blood glucose measurements of non-glucose-specific blood glucose meters resulting in falsely elevated blood glucose measurements (Schleis, 2007). Glucose meters that use strips containing glucose dehydrogenase pyrroloquinolinequinone (GDH-PQQ) or glucose dye oxidoreductase as the enzymatic assay are susceptible to this interaction (Health Canada, 2008). On average, the use of icodextrin can increase blood glucose readings by approximately 3.6 [+ or -] 1.4 mmol/L in these blood glucose meters, but the reading may be higher (Schleis, 2007). However, no conversion factor can be used because the over-estimation varies widely.

Blood glucose meters

The safest way for patients using icodextrin dialysis solution to monitor their blood glucose is with a blood glucose meter that uses a glucose-specific assay. The following assays are glucose specific (Health Canada, 2008).

* Dehydrogenase-nicotinamide adenine dinucleotide

* Glucose dehydrogenase flavin adenine dinucleotide

* Glucose oxidase

* Glucose hexokinase

To assist renal nurses with blood glucose meter selection for patients who use icodextrin PD solution, Table One provides details on some of the currently available blood glucose meters that should not be used. Table Two provides details on some of the currently available blood glucose meters that can be used. Information was obtained via verbal correspondence with each respective company on October 8, 2009.

Mr. BP observed that his blood glucose levels had increased after starting dialysis. It is important for the health care team to assess his current blood glucose meter before responding to his blood glucose levels. Raising his insulin doses due to falsely elevated blood glucose levels places him at increased risk of hypoglycaemic reactions including hypoglycaemic coma.
Table One. Blood glucose meters that may falsely elevate blood glucose
readings and therefore should NOT be used in patients receiving
icodextrin (Extraneal) peritoneal PD solution

Company     Blood glucose meter

Abbott   All FreeStyle:

         FreeStyle[R]
         FreeStyle Freedom[R]
         FreeStyle Flash[R]
         FreeStyle Lite[R]
         FreeStyle Freedom Lite[R]

Roche    ACCU-CHEK Compact Plus
         ACCU-CHEK Aviva
         ACCU-CHEK Aviva Nano

Table Two. Blood glucose meters that will not falsely elevate blood
glucose readings and therefore CAN be used in patients receiving
icodextrin (Extraneal) peritoneal PD solution

Company              Blood glucose meter

Abbott             Precision Xtra[R]

Bayer              Contour[R]
                   Breeze II[R]

LifeScan           All LifeScan Meters:

                   OneTouch[R] Select[TM]
                   OneTouch[R] Ultra[R]
                   InDuo[R] System
                   OneTouch[R] Basic [R]
                   OneTouch[R] SureStep[R]
                   OneTouch[R] Fast Take[R]
                   OneTouch[R] Profile[R]
                   OneTouch[R] UltraMini
                   OneTouch[R] Ultra 2
                   OneTouch[R] UltraSmart
                   OneTouch[R] UltraLink

Roche              ACCU-trend GC

Tremblay Harrison  Oracle[R]


When initiating icodextrin solution for diabetic PD patients, it is imperative for nephrology health care practitioners to review the type of blood glucose meter the patient is using at home and to ensure that it is compatible with icodextrin PD solutions. This will assist in decreasing the erroneous administration of insulin and potentially dangerous hypoglycaemic events.

References

Baxter. (n.d.). Baxter PD--The Role of EXTRANEAL (icodextrin) Peritoneal Dialysis Solution in Fluid Management. Retrieved March 26, 2009, from http://www.renalsource.com/extraneal/fluid.html

Health Canada. (2008). Health Canada Issued Important Safety Information on Possible interference of icodextrin, intravenous immunoglobulins, galactose and d-xylose with certain blood glucose monitors. Retrieved October 9, 2009, from http://www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/_2008/gluc_met_nth-aah-eng.php

Riley, S.G., Chess, J., Donovan, K.L., & Williams, J.D. (2003). Spurious hyperglycaemia and icodextrin in peritoneal dialysis fluid. British Medical Journal, 372(7415), 608-609.

Schleis, T.G. (2007). Interference of Maltose, Icodextrin, Galactose, or Xylose with some blood glucose monitoring systems. Pharmacotherapy, 27(9), 1313-1321.

By Jenny Ng, BScPhm,ACPR, RPh, and Marion Elligsen, BScPhm, RPh

Jenny Ng BSc.Phm, ACPR, RPh is Renal Pharmacist, Sunnybrook Health Sciences Centre, Toronto, ON

Marion Elligsen, BSc.Phm, RPh is Pharmacy Fellow, Sunnybrook Health Sciences Centre, Toronto, ON

Correspondence to: Jenny Ng, BScPhm, ACPR, RPh, Renal Pharmacist, Sunnybrook Health Sciences Centre, 2075 Bayview Ave., Toronto, ON M4N 3M5 E-mail: Jenny.Ng@Sunnybrook.ca

Department editor: Eleanor Ravenscroft, RN, PhD, CNeph(C)
COPYRIGHT 2009 Canadian Association of Nephrology Nurses & Technologists
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2009 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Practice corner
Author:Ng, Jenny; Elligsen, Marion
Publication:CANNT Journal
Date:Oct 1, 2009
Words:1019
Previous Article:New CANNT board members 2009-2010.
Next Article:Advance care planning and pain management in chronic kidney disease.
Topics:


Related Articles
Dialysis Therapy for Patients with Chronic Kidney Failure.
Kidney failure: choosing a treatment that's right for you.
Treatment methods for kidney failure: peritoneal dialysis.
Development of a peritoneal dialysis support initiative for clients in the community.
Elevated glycosylated hemoglobin levels in peritoneal dialysis patients: is it all about the glucose load?
Pyridoxal phosphate and hepatocyte growth factor prevent dialysate-induced peritoneal damage.
Positive interference of icodextrin metabolites in some enzymatic glucose methods.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters